Jim Clemmer, who has led AngioDynamics since April 2016, announced that he will retire after the appointment of a new chief executive officer. Clemmer will remain in the role until a successor is named, and the board has formed a search committee with an executive search firm to identify a replacement. The retirement announcement was made on January 6, 2026, the same day the company released its second‑quarter fiscal 2026 earnings.
AngioDynamics reported second‑quarter fiscal 2026 revenue of $79.4 million, beating the consensus estimate of $76.3 million by $3.1 million, or 4.1%. Earnings per share were $0.00, a breakeven figure that surpassed the consensus of a $0.10 loss, representing a $0.10 beat. Gross margin expanded to 56.4%, up 170 basis points year‑over‑year, driven by a favorable product‑mix shift toward the Med Tech segment, which grew 13% and contributed to the margin lift. The company’s Auryon platform also posted double‑digit growth, reinforcing the strategic focus on high‑margin, high‑growth medical‑device solutions.
During the earnings call, Clemmer highlighted the strong performance: “We delivered strong results in the second quarter. Revenue grew 8.8%, with Med Tech up 13%, and we translated that top‑line performance into improved profitability.” He also confirmed his retirement plans, saying, “I have informed the board of my intention to retire after a decade with the company and will continue to oversee strategic and financial initiatives until a successor is named.”
Management raised its full‑year fiscal 2026 guidance, increasing revenue guidance to $4.396 billion–$4.400 billion from $4.140 billion–$4.150 billion and raising adjusted operating‑income guidance to $2.151 billion–$2.155 billion from $2.100 billion–$2.110 billion. The guidance lift reflects confidence in sustained demand for Med Tech products, ongoing cost‑control initiatives, and the momentum of the Auryon platform. The company also reiterated its commitment to maintaining a strong cash position, noting that cash exceeds debt on the balance sheet.
Investors weighed the company’s robust earnings against the uncertainty introduced by the CEO transition. While the earnings beat and guidance raise signaled operational strength, the announcement of Clemmer’s retirement introduced a degree of uncertainty that tempered enthusiasm. Market participants are closely monitoring the search process and the potential impact on strategic execution.
AngioDynamics continues to focus on its Med Tech portfolio, which has delivered double‑digit revenue growth and margin expansion. The company’s strategic transformation has shifted resources toward high‑margin platforms, and the Auryon platform remains a key growth driver. Headwinds such as tariff impacts and cost pressures persist, but the company’s improved gross margin and raised guidance suggest that it is managing these challenges effectively. The strengthened cash position provides a buffer for continued investment in product development and potential acquisitions, positioning AngioDynamics for sustained growth in the coming years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.